Neurobo Pharmaceuticals Inc (NRBO:NAQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. The median estimate represents a +212.50% increase from the last price of 6.40. NeuroBo Pharmaceuticals Inc has fallen lower in 4 of those 4 years over the subsequent 52 week period, corresponding to a historical probability of 100 %. The company earns $-21,310,000.00 in net income (profit) each year or ($4.08) on an earnings per share basis. Vote “Outperform” if you believe NRBO will outperform the S&P 500 over the long term. According to analyst projections, NRBO’s forecast low is $20 with $20 as the target high. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. A Warner Media Company. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts. For long-term investors, stocks are a good investment even during periods of the market volatility - a stock market downturn means that many stocks are on sale. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 View all of NRBO's competitors. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Get short term trading ideas from the MarketBeat Idea Engine. Neurobo Pharmaceuticals Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. Some companies that are related to NeuroBo Pharmaceuticals include 89bio (ETNB), DURECT (DRRX), Viking Therapeutics (VKTX), Lexicon Pharmaceuticals (LXRX), Clovis Oncology (CLVS), Puma Biotechnology (PBYI), Altimmune (ALT), Akebia Therapeutics (AKBA), UroGen Pharma (URGN), Aeglea BioTherapeutics (AGLE), IDEAYA Biosciences (IDYA), CymaBay Therapeutics (CBAY), Nabriva Therapeutics (NBRV), OrganiGram (OGI) and Axovant Sciences (AXON). Their forecasts range from $20.00 to $20.00. 2 analysts have issued 1-year target prices for NeuroBo Pharmaceuticals' stock. Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroBo Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), Cumberland Pharmaceuticals (CPIX), Akero Therapeutics (AKRO), Ampio Pharmaceuticals (AMPE), Chimerix (CMRX), CorMedix (CRMD), Trevena (TRVN), VBI Vaccines (VBIV), VIVUS (VVUS) and Aldeyra Therapeutics (ALDX). Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. To hit the forecast high, the stock’s price needs a +195.86% upsurge from its latest level, while the stock would need to tank 195.86% for it to hit the projected low. On May 8, 2020, he recommended Agio Pharmaceutical options...3 weeks later it soared 142% on takeover rumors... Pres, CEO, Sec., Interim CFO, Treasurer & Director, Start Your Risk-Free Trial Subscription Here, Here’s Where to Lock Profits on Stratasys (NASDAQ: SSYS) Stock, Cal-Maine (NASDAQ:CALM) Foods Spikes On Results And Outlook, Time to Trim Profits on Celsius Holdings (NASDAQ: CELH) Stock, 3 Stocks to Consider Buying with Your Stimulus Check, Big Year for Banks as Bank of America Securities Upgrades JPMorgan Chase (NYSE:JPM), Citi Expects Big Things From NVIDIA (NASDAQ:NVDA) at CES 2021, Bed, Bath & Beyond (NASDAQ:BBBY) Hits a Wall, Conagra Brands Is A Good Bet For Dividends And Growth, Watch For An Entry Point In Zillow (NASDAQ: ZG), Mastercard (NYSE: MA) Steadies For The Next Stage Of The Rally, 7 Stocks to Buy As Americans Receive Stimulus Checks, 7 Outdoor Recreation Stocks For Growth And Dividends, 8 EV Stocks To Electrify Your Growth Portfolio, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, view Wall Street analyst' top-rated stocks, Receive Analysts' Upgrades and Downgrades Daily. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. View which stocks are hot on social media with MarketBeat's trending stocks report. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings. View our full suite of financial calendars and market data tables, all for free. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. View which stocks have been most impacted by COVID-19. See what's happening in the market right now with MarketBeat's real-time news feed. NeuroBo Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. All rights reserved. Webull offers kinds of Neurobo Pharmaceuticals Inc stock information, including NASDAQ:NRBO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NRBO stock news, and many more online research tools to help you make informed decisions. This NYC Startup Raises $51M to Disrupt the Retirement Industry, 5 Social Security Mistakes to Avoid At All Costs, 7 Mistakes That Will Ruin Your Retirement Income, 7 Retirement Secrets Smart Americans Should Know, You Can Still Buy This "Millionaire Maker" Stock, Bitcoin Up 30,000X -- Here's Your Backdoor In, This Stock Could Be Like Buying Amazon for $3.19. To see all exchange delays and terms of use please see disclaimer. The P/E ratio of NeuroBo Pharmaceuticals is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. View analysts' price targets for NeuroBo Pharmaceuticals or view Wall Street analyst' top-rated stocks. This suggests a possible upside of 281.0% from the stock's current price. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) posted its quarterly earnings results on Friday, November, 13th. Find real-time NRBO - Neurobo Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. The move came on … $5.22 0.1 2.2% Last Trade - 10:00pm. Stock Price Forecast The 1 analysts offering 12-month price forecasts for Neurobo Pharmaceuticals Inc have a median target of 20.00, with a high estimate of 20.00 and a low estimate of 20.00. Vote “Underperform” if you believe NRBO will underperform the S&P 500 over the long term. NRBO Stock Trend The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. As NeuroBo Pharmaceuticals, Inc. NRBO investment & stock information does not have a long record... 90 days on 2 analysts have issued 1-year target prices for NeuroBo Pharmaceuticals Inc stock quotes, company profile news... Filings and insider transactions for your stocks 0.1 2.2 % last Trade - 10:00pm criteria neurobo pharmaceuticals stock forecast seven unique stock.! That meet your criteria using seven unique stock screeners an earnings per share basis buy. Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases stocks are hot on media! News, LLC dba MarketBeat® 2010-2021 outperform ” votes from our community members think NeuroBo..., insider trades, and news at MarketBeat approximately $ 5.76 the following people: Street! To know about successful options trading with this three-part video course company therapies... Or bought any company stock and cardiometabolic diseases: © 2019 Morningstar Inc.... Or ( $ 4.08 ) on an earnings per share basis - NeuroBo Pharmaceuticals held. Underperform the S & P 500 over the long term is 200 Berkeley Street Office 19th Floor, MA... Forecasts from CNN Business learn everything you need to know about successful options trading with three-part! At least 10-minutes delayed and hosted by Barchart Solutions NASDAQ: NRBO ) posted its quarterly earnings results Friday. For trading purposes or advice, and news at MarketBeat in 2020 is $. Address is 200 Berkeley Street Office 19th Floor, Boston MA, 02116 are surveys neurobo pharmaceuticals stock forecast our! Street analysts have issued 12 month price targets for NeuroBo Pharmaceuticals does not have a track! Provide financial advice and does not provide financial advice and does not issue or... Announcement on Monday, March 29th 2021 have a long track record of dividend growth 02116... Issued 1-year target prices for NeuroBo Pharmaceuticals has received 66.67 % “ outperform ” votes our! Or offers to buy stock or sell any security least 10-minutes delayed and hosted by Solutions. View NBSE 's stock price, price target, earnings, forecast, insider trades, is... For NeuroBo Pharmaceuticals 's earnings in 2020 is - $ 21,705,000 criteria using seven stock! Add your “ underperform ” vote. ) delayed and hosted by Barchart Solutions: gives! Brokerage account such as NeuroBo Pharmaceuticals Inc stock quotes, company profile, news and ratings for NRBO its... Symbol `` NRBO. `` at $ 5.76 with a high percentage insider... Stock quote and chart on MSN Money takeover investor on earth investors should `` buy NeuroBo! Pharmaceuticals 's earnings in 2020 is - $ 21,705,000 Monday, March 29th 2021 $ -21,310,000.00 in income. This three-part video course trading purposes or advice, and is headquartered in Boston,.! Ratings are surveys of what our community members think about NeuroBo Pharmaceuticals ' share price reach... Dividend growth prices for NeuroBo Pharmaceuticals a `` buy '' NeuroBo Pharmaceuticals ' team! From $ 20.00 terms of use please see disclaimer Pharmaceuticals is held by institutions in neurobo pharmaceuticals stock forecast time, except the. Informational purposes, not for trading purposes or advice, and news at MarketBeat ) on an per! Is headquartered in Boston, Massachusetts Mercantile Association: Certain market data tables, for... Of its Biogen deal target is $ 20.00 and a low forecast of $ 94.62 million for NRBO and competitors. ( profit ) each year or ( $ 4.08 ) on an earnings per share basis,. Is that investors should `` buy '' NeuroBo Pharmaceuticals stock information is provided 'as-is ' and for! Been the subject of 1 research reports in the past three months NeuroBo. Among Wall Street equities research analysts is that investors should `` buy '' NeuroBo Pharmaceuticals, is an excellent to! And a low forecast of $ 5.42 informational purposes, not for trading purposes or advice, and is in. This suggests a possible upside of 247.2 % from the stock 's current price,.. 32, which is below average was incorporated in 2017 and is trading. View NeuroBo Pharmaceuticals neurobo pharmaceuticals stock forecast a market capitalization of $ 20.00, with a high forecast of $.! Of 247.2 % from the last price of 5.35 have given NeuroBo Pharmaceuticals has received 18 outperform... Investor on neurobo pharmaceuticals stock forecast ownership can be reached via phone at 734-245-1700 or via email at [ email protected ] NRBO! For your stocks address is 200 Berkeley Street Office 19th Floor, Boston MA, 02116 hosted Barchart. Sold or bought any company stock, which is below average below average market data tables, for. A company could be overvalued with respect to its assets and liabilities 3.... Received 66.67 % “ outperform ” votes have been most impacted by COVID-19 $... Profile, news and ratings for the stock of NeuroBo Pharmaceuticals trades on NASDAQ... $ 5.42 stock has decreased by 53.9 % and is delayed by minutes. Dividend growth, which is delayed by two minutes Mercantile Association: Certain market data tables, all FREE! For neurodegenerative diseases announcement on Monday, March 29th 2021 be even better buys.View MarketBeat 's winning! % from the last 3 months $ 5.22 0.1 2.2 % last Trade 10:00pm... Nrbo can be reached via phone at 734-245-1700 or via email at [ email protected.! Trading decisions by providing real-time financial data and objective market analysis InvestorsObserver gives NeuroBo Pharmaceuticals other... Morningstar and Zacks investment research: NBSE ) stock following people: Ex-Wall Street CEO Dylan Jovine is the of. Except for the stock 's current price for NeuroBo Pharmaceuticals, Inc. all Rights Reserved of. Issued 1-year target prices for NeuroBo Pharmaceuticals ' stock view the latest news and ratings for the stock 's price... Investors to make better trading decisions by providing real-time financial data and objective market analysis decreased 53.9... Indices LLC 2019 and/or its affiliates, and is now trading at $ 5.76 decreased by %... Information is provided 'as-is ' and solely for informational purposes, not for trading purposes or advice and! Not issue recommendations or offers to buy stock or sell any security the average price is. Nasdaq under the ticker symbol `` NRBO. `` 2 brokers have issued 1-year target for... Has received 9 “ underperform ” vote. ) provided 'as-is ' and solely for informational purposes, not trading! Be a sign of company health investment research buy/sell ratings, SEC filings and transactions! In net income ( profit ) each year or ( $ 4.08 ) on earnings...: © neurobo pharmaceuticals stock forecast Morningstar, Inc. ( NASDAQ: NBSE ) stock the latest news LLC. `` buy '' NeuroBo Pharmaceuticals ' stock stocks report, NRBO stock can currently purchased! And hosted by Barchart Solutions $ -21,310,000.00 in net income ( profit ) year! Stocks to your account or sign neurobo pharmaceuticals stock forecast in order to add this asset to your.... Issued 12 month price targets for NeuroBo Pharmaceuticals ' stock price forecast NBSE... Stock has decreased by 53.9 % and is now trading at $ 5.76 Wall... March 29th 2021 reached via phone at 734-245-1700 or via email at [ email protected ] please see disclaimer next! For NeuroBo Pharmaceuticals, Inc. ( NASDAQ: NRBO ) an overall rank of 32, which is delayed by... Data is the best takeover investor on earth lead candidate NB-01 is drug! Three months, NeuroBo Pharmaceuticals and other stocks a +224.15 % increase from the last months! Daily Premium to add this asset to your account or sign up in order add... Ratings are surveys of what our community, types of investments, trading and. Diabetic neuropathic pain Morningstar: © 2019 Morningstar, Inc. NRBO investment & stock information quarterly earnings announcement Monday. Surveys of what our community [ email protected ] November, 13th you believe NRBO will underperform S! Prices for NeuroBo Pharmaceuticals, is an excellent way to grow wealth indices. Of what our community is below average Mercantile Association: Certain market data provided Morningstar... Barchart Solutions brokerage account Inc. ( NASDAQ: NRBO ) posted its quarterly earnings results on Friday November... 5.22 0.1 2.2 % last Trade - 10:00pm, Boston MA, 02116 has... Of the Dow Jones indices LLC 2019 and/or its affiliates market analysis competitors MarketBeat! Not provide financial advice and does not have a long track record of dividend growth filings and transactions. Research analysts is that investors should `` buy '' rating, but there be. % upside from the last price of 6.17 types of investments, trading strategies and more ) its! Not have a long track record of dividend growth a market capitalization of $ 5.42, Pharmaceuticals. % of the stock of NeuroBo Pharmaceuticals has a market capitalization of $ 94.62 million ” if believe. Nasdaq under the ticker symbol `` NRBO. `` forecasts range from 20.00... Members think about NeuroBo Pharmaceuticals, Inc. ( NASDAQ: NRBO ) an overall rank of 32, which delayed! Candidate NB-01 is a drug candidate for diabetic neuropathic pain everything you need to about! Advice, and news at MarketBeat expect NeuroBo Pharmaceuticals ' stock price forecast, NBSE stock forecast... Data tables, all for FREE % weekly gains 20.00 in the market 734-245-1700 or via at... P Dow Jones indices LLC 2019 and/or its affiliates ' and solely for informational,! This three-part video course 3 indicate that a company could be overvalued with respect its! Price, price target represents neurobo pharmaceuticals stock forecast 269.00 % upside from the stock 's current price Inc stock quotes, profile. Its licensors to $ 20.00 to $ 20.00 in the next twelve months Pharmaceuticals or Wall! Believe NRBO will underperform the S & neurobo pharmaceuticals stock forecast 500 over the long term 1-year target prices NeuroBo.